Monoclonal antibody therapies have been shown to remove amyloid plaques and slow Alzheimer's progression in symptomatic patients. However, their ability to delay symptom onset in asymptomatic individuals remains unclear. To address this gap, researchers have investigated the impact of gantenerumab on 73 individuals genetically predisposed to developing Alzheimer’s disease (AD). The study found that long-term gantenerumab treatment (eight years) delayed symptom onset and slowed dementia progression.
Notably, individuals in the longest-treated group had a 50% lower risk of developing symptoms. Although amyloid-related imaging abnormalities were reported in 30% of participants, no life-threatening adverse events occurred. These findings suggest that prolonged gantenerumab use may delay symptom onset in at-risk individuals. However, its pharmaceutical developers discontinued further…
